Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology. 2001;57(6):1044–50.

Article  CAS  PubMed  Google Scholar 

Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132–8.

Article  PubMed  Google Scholar 

Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3):558–63.

Article  PubMed  Google Scholar 

Botox [package insert]. Irvine, CA: Allergan, Inc. 2018.

Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009;55(1):100–19.

Article  CAS  PubMed  Google Scholar 

Kuschel S, Werner M, Schmid DM, Faust E, Schuessler B. Botulinum toxin-a for idiopathic overactivity of the vesical detrusor: a 2-year follow-up. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(7):905–9.

Article  PubMed  Google Scholar 

Lo W, Lo M. Botulinum toxin-A (boNT/A) in the treatment of idiopathic detrusor overactivity (IDO) incontinence. A prospective randomized study to compare 20 vs. 10 injection sites. BJU Int. 2015;116(4):8.

Google Scholar 

Cohen BL, Rivera R, Barboglio P, Gousse A. Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection. J Urol. 2007;177(3):1006–10 (discussion 1010).

Article  PubMed  Google Scholar 

Chang ES, Ringel N, Woodburn KL, et al. Postprocedural pain associated with 5 versus 20 intradetrusor injections of onabotulinumtoxinA for treatment of overactive bladder: a multicenter randomized clinical trial. Urogynecology (Phila). 2022;28(8):518–25.

PubMed  Google Scholar 

Coyne KS, Thompson CL, Lai JS, Sexton CC. An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF. Neurourol Urodyn. 2015;34(3):255–63.

Article  PubMed  Google Scholar 

Smith CP, Chancellor MB. Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol. 2005;19(7):880–2.

Article  PubMed  Google Scholar 

Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986;27(1):117–26.

Article  PubMed  Google Scholar 

Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004;27(1):26–35.

Article  PubMed  Google Scholar 

DiCarlo-Meacham AM, Dengler KL, Welch EK, et al. Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder. Neurourol Urodyn. 2023;42(1):366–74.

Article  CAS  PubMed  Google Scholar 

Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93.

Article  CAS  PubMed  Google Scholar 

Faure Walker N, Macpherson F, Tasleem A, Rampal T. Interventions to improve tolerability of local anesthetic intradetrusor botulinum toxin injections: a systematic review. Neurourol Urodyn. 2023;42(1):23–32.

Article  PubMed  Google Scholar 

Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–22.

Article  CAS  PubMed  Google Scholar 

Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin a (botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol. 2008;53(2):275–87.

Article  CAS  PubMed  Google Scholar